Mirati Therapeutics, Inc. - Common Stock (NQ:MRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirati Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

December 20, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Analyst Expectations For Mirati Therapeutics's Future ↗

December 20, 2023

Via Benzinga

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

November 29, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

What 11 Analyst Ratings Have To Say About Mirati Therapeutics ↗

November 07, 2023

Via Benzinga

3 Resilient Stocks with Massive Potential to Boost Your Wealth ↗

November 26, 2023

These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.

Via InvestorPlace

These Three Biotech Stocks Are Trading At A Discount ↗

November 23, 2023

Investors exposed to the biotech sector have seen mixed results this year.

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 17, 2023

Via Benzinga

3 Biotech Stocks That Could Boom or Bust by 2025 ↗

November 16, 2023

Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.

Via InvestorPlace

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

November 08, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

3 No-Brainer Stocks to Buy With $500 Right Now ↗

November 08, 2023

A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.

Via The Motley Fool

Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 07, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

Is MIRATI THERAPEUTICS INC Ready to Break Out of Its Range? ↗

November 06, 2023

Investors are keeping a close eye on MIRATI THERAPEUTICS INC (NASDAQ:MRTX) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout.

Via Chartmill

7 Healthcare Stocks That Can Cure a Lackluster Portfolio ↗

October 19, 2023

Take a position in these companies' stocks to achieve long-term gains and give a jolt to your investment portfolio.

Via InvestorPlace

Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings ↗

October 19, 2023

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or...

Via Benzinga

Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

October 17, 2023

Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...

Via PressReach

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE

October 16, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade ↗

October 11, 2023

The company has growing pipeline optionality, according to the upgrade report.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗

October 10, 2023

Via Benzinga

Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

October 10, 2023

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...

Via PressReach

MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

October 09, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 09, 2023

Via Benzinga

Why Shares of Tango Therapeutics Are Dropping Monday ↗

October 09, 2023

Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023 ↗

October 09, 2023

Via Benzinga

Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 09, 2023

Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near...

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)

October 09, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid ↗

October 09, 2023

Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.

Via Investor's Business Daily

Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal ↗

October 09, 2023

Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total

Via Benzinga

S&P 500, Nasdaq Set For Bleak Start To Week As Middle East Tensions Dampen Risk-On Mood: Earnings, Inflation Data In Focus ↗

October 09, 2023

Trading in stock futures suggests a lower open on Monday as traders digest the ramification of the conflict in the Middle East.

Via Benzinga

Topics Economy Stocks

Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 09, 2023

U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.